Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03568916
Other study ID # Q16-13A
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 2016
Est. completion date November 2016

Study information

Verified date January 2021
Source Canadian Network for Observational Drug Effect Studies, CNODES
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to assess safety and effectiveness of direct oral anticoagulants (DOACs) for stroke prevention in patients with non-valvular atrial fibrillation (AF). The comparison of DOACs between themselves is of interest. The investigators will carry out separate population-based, matched cohort studies, using health administrative databases in nine jurisdictions in Canada, the UK and the US. New users of DOACs for stroke prevention in non-valvular AF will be eligible to enter the cohorts. Follow-up will continue until a hospitalization or emergency department visit for a stroke. The results from the separate sites will be combined by meta-analysis to provide an overall assessment of the safety and effectiveness of the different anticoagulation regimens in stroke prevention in AF. The investigators hypothesize that different DOACs will have similar safety and effectiveness profiles.


Description:

The objective of this study is to assess safety and effectiveness of direct oral anticoagulants (DOACs) for stroke prevention in patients with non-valvular atrial fibrillation (AF). A common-protocol approach will be used to conduct retrospective cohort studies using administrative health care data from nine jurisdictions (the Canadian provinces of Alberta, British Columbia, Manitoba, Nova Scotia, Ontario, Quebec, Saskatchewan, as well as the United Kingdom (UK) Clinical Practice Research Datalink (CPRD) and the United States (US) Marketscan). Briefly, the Canadian databases include population-level data on physician billing, diagnoses and procedures from hospital discharge abstracts, and dispensations for prescription drugs. The data in Alberta, Nova Scotia, and Ontario will be restricted to patients aged 65 years and older, as prescription data are not available for younger patients. The CPRD is a clinical database that is representative of the UK population and contains the records for patients seen at over 680 general practitioner practices in the UK; these data will be linked to the Hospital Episode Statistics (HES) database, which contains in-hospital diagnosis and procedure data. US MarketScan includes individuals and their dependents covered by large US employer health insurance plans, and government and public organizations. In each jurisdiction, the investigators will assemble a base cohort that includes all patients newly prescribed a DOAC for stroke prevention in AF. Study period will be from the date of the first DOAC approval for stroke prevention in AF at each site to the date of latest data availability at each site. All patients newly dispensed a DOAC (i.e. with no prescription for any oral anticoagulant in the prior year) with a diagnosis of AF within the 3 years prior to the date of the prescription will be eligible to be included into the study cohorts, given they present no exclusion criteria. The date of study cohort entry will be defined by the prescription (for CPRD) or dispensation (for all other sites) date of the newly prescribed DOAC. Patients will be censored at the earliest of death, end of healthcare coverage, or the end of the study period, whichever occurs first. Exposure to a DOAC will be defined as a new prescription for a DOAC (apixaban, dabigatran, rivaroxaban) on the date of cohort entry. The investigators will use an analysis analogous to an intention-to-treat approach. The primary outcome will be defined as a hospitalization or emergency department visit for ischemic stroke or systemic embolization. The secondary outcomes will be: 1) major bleeding; 2) a composite of stroke (ischemic or hemorrhagic), systemic embolization, major bleeding or all-cause mortality; 3) myocardial infarction; 4) gastrointestinal bleeding; 5) intracranial bleeding; and 6) all-cause mortality. The study cohort will be analyzed using a matched cohort design. In each participating site, three distinct study cohorts will be assembled, one for each of the following comparisons, nested in the same base cohort: 1) dabigatran vs. rivaroxaban, 2) dabigatran vs. apixaban, and 3) rivaroxaban vs. apixaban. DOAC users will be matched 1:1 to DOAC users on sex, age, cohort entry date, and propensity score (which will be constructed using a multivariable logistic regression model estimating the odds of being treated with DOACs, while adjusting for a number of pre-identified covariates to account for baseline differences at the time of cohort entry). Cox-proportional hazards regression models will be used to estimate adjusted hazards ratios (HRs) and corresponding 95% confidence intervals (CIs) for ischemic stroke or systemic embolization in the three cohorts. Meta-analyses of the site-specific results will be performed using random effects models. As secondary analyses, the composite outcome will be stratified by age (<85 and ≥85) and sex. In addition, an as treated analysis using inverse probability of censoring weights (IPCW) will be performed to account for non-random censoring.


Recruitment information / eligibility

Status Completed
Enrollment 227579
Est. completion date November 2016
Est. primary completion date November 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with a new prescription for an oral anticoagulant that had a diagnosis of atrial fibrillation or atrial flutter within the 3 years prior to the date of the prescription - Patients aged 18 years or older (except Alberta, Nova Scotia, and Ontario, where patients will be aged at least 66 years or older) Exclusion Criteria: - Patients with less than one year of data availability prior to cohort entry - Patients with a diagnosis of valvular disease (including rheumatic heart disease) or prior cardiac valve surgery - Patients with a diagnosis of venous thromboembolic disease in the year prior to cohort entry - Patients who underwent hemodialysis in the 90 days prior to cohort entry - Patients with a hip, femur, or knee surgery in the 30 days prior to cohort entry - Patients with a diagnosis of antiphospholipid syndrome

Study Design


Intervention

Drug:
Apixaban (ATC B01AF02)
Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
Dabigatran (ATC B01AE07)
Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
Rivaroxaban (ATC B01AF01)
Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.

Locations

Country Name City State
Canada Centre de recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM) Montréal Quebec

Sponsors (3)

Lead Sponsor Collaborator
Canadian Network for Observational Drug Effect Studies, CNODES Canadian Institutes of Health Research (CIHR), Drug Safety and Effectiveness Network, Canada

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Durand M, Schnitzer ME, Pang M, Carney G, Eltonsy S, Filion KB, Fisher A, Jun M, Kuo IF, Matteau A, Paterson JM, Quail J, Renoux C; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Effectiveness and safety among direct oral a — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Ischemic stroke (IS) or systemic embolization (SE) Patients hospitalized or visiting the emergency department for a stroke or a systemic embolization recorded as the most responsible diagnosis in either the discharge abstract or hospitalization record with the following ICD codes:
Ischemic stroke:
ICD-9 codes: 434.x ICD-10 codes: I63.x, I64.x
Systemic embolization:
ICD-9 codes: 444.x ICD-10 codes: I74.x
Patients will be followed from date of first DOAC prescription (cohort entry date) until a hospitalization or emergency department visit for IS or SE, censoring due to death, end of healthcare coverage, or for up to 65 months, whichever occurs first.
Secondary Major bleeding Patients hospitalized or visiting the ER for a major bleed composite recorded as the most responsible diagnosis in either the discharge abstract or hospitalization record with the following ICD codes:
Intracranial bleeding (including hemorrhagic stroke):
ICD-9 codes: 430.x, 431.x, 432.x ICD-10 codes: I60.x, I61.x, I62.x
Gastrointestinal bleeding:
ICD-9 codes: 456.0, 531.0, 531.2, 531.4, 531.6, 532.0, 532.2, 532.4, 532.6, 533.0, 533.2, 533.4, 533.6, 534.0, 534.2, 534.4, 534.6, 569.3, 578.x ICD-10 codes: I85.0, I98.3, K25.0, K25.2, K25.4, K25.6, K26.0, K26.2, K26.4, K26.6, K27.0, K27.2, K27.4, K27.6, K28.0, K28.2, K28.4, K28.6, K29.0, K55.21, K62.5, K63.81, K92.0, K92.1, K92.2
Ocular bleeding:
ICD-9 codes: 362.81, 363.6x, 376.32, 379.23, 377.42 ICD-10 codes: H31.3, H35.6, H43.1, H45.0
Other bleeding causing ER visit or hospitalization:
ICD-9 codes: 459.0, 596.7, 599.7, 627.1, 719.1, 729.92, 784.7, 784.8, 786.3 ICD-10 codes: D68.3, K66.1, M25.0x, N02.x
Patients will be followed from date of first DOAC prescription (cohort entry date) until a hospitalization or emergency department visit for major bleed, censoring due to death, end of healthcare coverage, or for up to 65 months, whichever occurs first.
Secondary All-cause mortality Patients will be followed from date of first DOAC prescription (cohort entry date) until death, end of healthcare coverage, or for up to 65 months, whichever occurs first.
Secondary Myocardial infarction Patients hospitalized for a myocardial infarction recorded as the most responsible diagnosis in hospitalization record with the following ICD codes:
ICD-9 code: 410.x ICD-10 code: I21.x
Patients will be followed from date of first DOAC prescription (cohort entry date) until a hospitalization for a myocardial infarction, censoring due to death, end of healthcare coverage, or for up to 65 months, whichever occurs first.
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A